Originally published by our sister publication Clinical Oncology News
By Kate O'Rourke
The FDA granted accelerated approval to pirtobrutinib (Jaypirca, Lilly) for relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of systemic therapy, including a Bruton’s tyrosine kinase (BTK) inhibitor.
Efficacy was evaluated in BRUIN, an open-label, multicenter, single-arm trial of pirtobrutinib monotherapy that included 120 patients with MCL previously treated with a BTK inhibitor.